| 2001 |
Dr. Bettina Doepner |
The Common Technical Document, Module 3 - Quality, Proposal for adaptation to herbal medicinal products |
|
|
| 2001 |
Dr. Susanne Donat |
Mechanistic considerations on the carcinogenic effects of fibrates |
|
|
| 2001 |
Dr. Jan Dütemeyer |
Information in the Internet about Medicinal Products Provided by Governmental Institutions in Germany, Great Britain and the United States |
|
|
| 2001 |
Karen Frischke |
The annex to Council Directive 75/318 and its consequences on new and existing marketing authorisations in the EC |
|
|
| 2001 |
Dr. Karin Heidenreich |
Review 2001: The future of the Mutual Recognition Procedure including special aspects of the EU-enlargement |
|
|
| 2001 |
Dr. Joachim Heinze |
Legal Basis of the Parallel Participation of the Principality of Lichtenstein in the European Economic Area and the Customs Union with Switzerland |
|
|
| 2001 |
Dr. Klaus Hohenleitner |
"The quality of the active substance - A look at the different regulatory requirements" |
|
|
| 2001 |
Dr. Alexander Kainz |
Developing biopharmaceuticals - Regulatory aspects of the safety evaluation of monoclonal antibodies in the United States and in Europe |
|
|
| 2001 |
Brigitte Nerl |
Maintenance of Generic Marketing Authorizations |
|
|
| 2001 |
Dr. Carolin Notheis |
Regulatory requirements concerning the quality of herbal medicinal products under the EU pharmaceutical and national food legislation |
|
|
| 2001 |
Dr. Katrin Sauerland |
The Demarcation of Medical Devices and Medicinal Products in the European Union |
|
|
| 2001 |
Dr. Jürgen Hans Schmidt |
From study protocol to final report -practical aspects and constructive input of the DRA/QA function in this process |
|
|
| 2001 |
Beate Schmidt-Krauthause |
Implementation of complaint management in a sales and distribution only company for pharmaceuticals |
|
|
| 2001 |
Kirsten Vonde |
Requirements an opportunities of an OTC-switch Comparison between Germany, UK and USA |
|
|
| 2001 |
Martin Wiesbeck |
E-Commerce and Homecare in Germany - Opportunities and Limitations |
|
|
| 2001 |
Anette Wiesemann-Fuhr |
Compare the FDA, EMEA and BfArM internet publication policy especially on approval, pharmacovigilance and Drugs on the horizon |
|
|
| 2000 |
Dr. Irmgard Buchkremer-Ratzmann |
Special features of the development and regulatory requirements of biotechnological products as defined by part A of the Annex of Commission Regulation 2309/93 |
|
|
| 2000 |
Dr. Christine Ernst |
Realisation der Wahrnehmung der Aufgaben des Informationsbeauftragten in einem Vertriebsunternehmen unter Berücksichtigung der Abgrenzung der Aufgabenbereiche des Vertriebsleiters sowie der Schnittstellendefinition mit einem Lizenzgeber und Implementierung in das QS-System |
|
|
| 2000 |
Susanne Kästner |
Review 2000 Review of Regulatory Procedure by the European Commission |
|
|
